Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

A-1331852

Catalog No: tcsc5565

Available Sizes

Size: 5mg

Size: 10mg

Size: 25mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
1430844-80-6

Formula:
$C_{38}H_{38}N_6O_3S$

Pathway:
Apoptosis

Target:
Bcl-2 Family

Purity / Grade:
>98%

Solubility:
DMSO : ≥ 50 mg/mL (75.89 mM); H2O :

Observed Molecular Weight:
658.81

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

Product Description

A-1331852 is an orally available **BCL-XL** selective inhibitor with a $\mathbf{K_i}$ of less than 10 pM.

IC50 & Target: Ki: less than 10 pM (BCL-XL)[1]

In Vitro: A-1331852 selectively disrupts BCL-XL–BIM complexes and induces the hallmarks of apoptosis in BCL-XL–dependent Molt-4 cells with IC_{50}s in the low nanomolar range but does not affect MEF cells lacking BAK or BAX. In CellTiter-Glo cell viability assay, A-1331852 inhibits NCI-H847, NCI-H1417, SET-2, HEL, OCI-M2 with EC_{50} values of 3, 7, 80, 120 and 100 nM[1].

In Vivo: A-1331852 demonstrates antitumor efficacy in the Molt-4 xenograft model, inducing tumor regressions as a single agent. Additionally, A-1331852 combines with venetoclax to recapitulate the efficacy of navitoclax in the NCI-H1963.FP5 xenograft model of SCLC. A-1331852 significantly inhibits tumor growth in seven subcutaneous xenograft models of solid tumors, including breast cancer, NSCLC, and ovarian cancer[1].